Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Open Access
- 7 September 2020
- Vol. 25 (18), 4096
- https://doi.org/10.3390/molecules25184096
Abstract
Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward.This publication has 121 references indexed in Scilit:
- T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer managementImmunoTargets and Therapy, 2013
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer CellsPLOS ONE, 2012
- T lymphocytes and normal tissue responses to radiationFrontiers in Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervixCellular & Molecular Immunology, 2010
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesBritish Journal of Cancer, 2009
- Chemotherapy Induces Tumor Clearance Independent of ApoptosisCancer Research, 2008
- Spontaneous tumor rejection by cbl-b–deficient CD8+ T cellsThe Journal of Experimental Medicine, 2007
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006
- Inflammation and necrosis promote tumour growthNature Reviews Immunology, 2004